Figure 2.
AB002 interrupts occlusive thrombus formation. (A) Real-time platelet accumulation within small diameter collagen-coated synthetic vascular grafts (2-mm i.d.; 20 mm length). Blood flow through the device was adjusted to 100 mL/min, producing an initial wall shear rate of 2120 sāˆ’1. Thrombi were allowed to grow for 15 minutes before treatment (black arrow). E-WE thrombin was given as an IV bolus (n = 3-6 per treatment group); controls (n = 5) received no treatment. Data are means plus or minus SEM. (B) Time to occlusion is shown. Horizontal bars denote mean of all data points. All control grafts occluded within 21 to 33 minutes. AB002 treatment significantly increased the time to occlusion (*P < .05; Gehan-Breslow-Wilcoxon test), with 8 of 12 grafts remaining patent for the entire 60 minutes.

AB002 interrupts occlusive thrombus formation. (A) Real-time platelet accumulation within small diameter collagen-coated synthetic vascular grafts (2-mm i.d.; 20 mm length). Blood flow through the device was adjusted to 100 mL/min, producing an initial wall shear rate of 2120 sāˆ’1. Thrombi were allowed to grow for 15 minutes before treatment (black arrow). E-WE thrombin was given as an IV bolus (n = 3-6 per treatment group); controls (n = 5) received no treatment. Data are means plus or minus SEM. (B) Time to occlusion is shown. Horizontal bars denote mean of all data points. All control grafts occluded within 21 to 33 minutes. AB002 treatment significantly increased the time to occlusion (*P < .05; Gehan-Breslow-Wilcoxon test), with 8 of 12 grafts remaining patent for the entire 60 minutes.

Close Modal

or Create an Account

Close Modal
Close Modal